Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more
Tvardi Therapeutics, Inc. (TVRD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.153x
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has a cash flow conversion efficiency ratio of -0.153x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($27.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tvardi Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tvardi Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EHEALTH
BE:M5V
|
-0.035x |
|
PORT OF TAURANGA LTD ORD
BE:PKF1
|
N/A |
|
SeqLL Inc.
PINK:ATLN
|
-0.083x |
|
The E W Scripps Co
STU:SQ6B
|
0.023x |
|
MCNCF
OTCGREY:MCNCF
|
N/A |
|
AERGP
PINK:AERGP
|
N/A |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
KINGFISHER (KFI1.SG)
STU:KFI1
|
N/A |
Annual Cash Flow Conversion Efficiency for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +3811.96% |
| 2023-12-31 | $-62.06 Million | $-21.04 Million | 0.339x | -14.51% |
| 2022-12-31 | $-45.05 Million | $-17.87 Million | 0.397x | +250.16% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | -- |